Each tumor does not only trigger immune responses aiming to control its growth, but also causes profound immune dysregulation in the host. Chronic antigen stimulation, contact-dependent effects through invariant receptors, and paracrine or systemic release of mediators induce a plethora of alterations on virtually every immune cell type in the body. Their precise characterization across cancer entities is of key importance for the development of novel immunomodulatory strategies, individualization of therapeutic interventions, and improved patient monitoring. Recent advances in methods of cellular and molecular immunology, the resounding success of PD-(L)1 inhibitors across a wide spectrum of oncological indications, along with emerging "next-generation immunotherapeutics", like cell therapies and multispecific antibodies, make this task today more relevant than ever.
This Research topic aims to provide a broad and comprehensive overview about recent discoveries in the field of cancer-associated systemic immune dysregulation. This includes numerical imbalances, alterations and functional defects in any immune cell type, across the entire spectrum of solid and hematological malignancies. Additional objectives are the identification of pathophysiologic links to the genetic contexture and immunologic microenvironment of cancer, the potential prognostic and predictive value of these alterations as biomarkers to guide patient management, and opportunities for direct therapeutic exploitation using novel drugs or in the context of cell therapies.
We welcome the submission of Original Research, Review, or Perspective articles including, but not limited to:
1. T-cell dysregulation in various cancers
2. T-cell function, TCR signaling, T-cell fitness, and the physiology of T-cell exhaustion
3. NK-/B-/Dendritic cell defects
4. Identification and validation of immunologic biomarkers for the characterization of immune status and/or therapy monitoring in cancer patients, especially using blood samples including liquid biopsies.
5. Studies on disease-specific patterns of immune dysregulation (e.g. particular alterations in specific solid tumors or hematologic malignancies).
6. Any method (pharmacologic or other) to restore immune function enhance the efficacy of immunotherapy in cancer patients, including preclinical and clinical studies
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Each tumor does not only trigger immune responses aiming to control its growth, but also causes profound immune dysregulation in the host. Chronic antigen stimulation, contact-dependent effects through invariant receptors, and paracrine or systemic release of mediators induce a plethora of alterations on virtually every immune cell type in the body. Their precise characterization across cancer entities is of key importance for the development of novel immunomodulatory strategies, individualization of therapeutic interventions, and improved patient monitoring. Recent advances in methods of cellular and molecular immunology, the resounding success of PD-(L)1 inhibitors across a wide spectrum of oncological indications, along with emerging "next-generation immunotherapeutics", like cell therapies and multispecific antibodies, make this task today more relevant than ever.
This Research topic aims to provide a broad and comprehensive overview about recent discoveries in the field of cancer-associated systemic immune dysregulation. This includes numerical imbalances, alterations and functional defects in any immune cell type, across the entire spectrum of solid and hematological malignancies. Additional objectives are the identification of pathophysiologic links to the genetic contexture and immunologic microenvironment of cancer, the potential prognostic and predictive value of these alterations as biomarkers to guide patient management, and opportunities for direct therapeutic exploitation using novel drugs or in the context of cell therapies.
We welcome the submission of Original Research, Review, or Perspective articles including, but not limited to:
1. T-cell dysregulation in various cancers
2. T-cell function, TCR signaling, T-cell fitness, and the physiology of T-cell exhaustion
3. NK-/B-/Dendritic cell defects
4. Identification and validation of immunologic biomarkers for the characterization of immune status and/or therapy monitoring in cancer patients, especially using blood samples including liquid biopsies.
5. Studies on disease-specific patterns of immune dysregulation (e.g. particular alterations in specific solid tumors or hematologic malignancies).
6. Any method (pharmacologic or other) to restore immune function enhance the efficacy of immunotherapy in cancer patients, including preclinical and clinical studies
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
